TP53 and myelodysplastic syndrome: The interplay between cytogenetic profile and prognostic power of specific mutations is highlighted by the finding that most MDS patients presenting with a complex karyotype also carry a mutation or a deletion in the well-known tumor suppresser gene TP53. 43,44 Whether the aberrant karyotype or the TP53 mutation is responsible for the poor outcome of affected patients is still unknown.